Report cover image

M&A Trends in Pharma - Q2 2025

Publisher GlobalData
Published Jul 16, 2025
Length 21 Pages
SKU # GBDT20290067

Description

M&A Trends in Pharma - Q2 2025

Summary

This report analyzes the merger and acquisition (M&A) activity in Q2 2025 in the Pharma sector.

The global pharma sector in Q2 2025 witnessed deals worth $32.9 billion, reflecting a decline of 11.6% compared to Q1 2025. In terms of deal volume, there was a decline of 12.8% to 130 M&A deals in Q2 2025. Oncology emerged as the leading therapeutic area recording 51 deals.

Scope
  • This report provides an overview of M&A activity globally in Q2 2025 in the Pharma sector involving biopharmaceutical drug companies.
  • It identifies key trends, and the most notable deals announced in Q2 2025 in the Pharma sector.
Reasons to Buy
  • Companies that make strategic investments in M&A position themselves for success, while those that fail to adapt risk falling behind.
  • This report provides an overview of global M&A trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.

Table of Contents

21 Pages
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Pharma M&A Activity in Q2 2025
2.1 Pharma Insights: Deal spotlight
3 Global M&A Trends in Pharma
4 Global Quarterly M&A Activity in Pharma
5 Ownership Type: Private Vs Public (Count)
6 Ownership Type: Private Vs Public (Value)
7 Global M&A Activity in Pharma by Deal Size
8 Notable Pharma Deals in Q2 2025
9 Pharma Regional Comparison - Q2 2025
10 Global Cross Border M&A Trends in Pharma
11 Inbound and Outbound Deals in Pharma in Q2 2025
12 Regional M&A Activity in Pharma by Value and Volume
13 Pharma M&A Review by Top 10 Countries
14 Top 10 Therapy Area M&A Review
15 Further Information
15.1 Methodology
16 Contact Us

Search Inside Report

How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.